PRPH (ProPhase Labs) Total Liabilities: $56.36 Mil (As of Dec. 2025)


What is ProPhase Labs Total Liabilities?

ProPhase Labs PRPH +9.77% Total Liabilities is $56.36 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

ProPhase Labs's Total Liabilities for the quarter that ended in Dec. 2025 was $56.36 Mil.

ProPhase Labs's quarterly Total Liabilities increased from Jun. 2025 ($30.61 Mil) to Sep. 2025 ($58.84 Mil) but then declined from Sep. 2025 ($58.84 Mil) to Dec. 2025 ($56.36 Mil).

ProPhase Labs's annual Total Liabilities increased from Dec. 2023 ($42.54 Mil) to Dec. 2024 ($55.85 Mil) and increased from Dec. 2024 ($55.85 Mil) to Dec. 2025 ($56.36 Mil).

ProPhase Labs Total Liabilities Historical Data

* Premium members only.

The historical data trend for ProPhase Labs's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs Total Liabilities Chart

ProPhase Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.67 24.02 42.54 55.85 56.36

ProPhase Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.85 34.99 30.61 58.84 56.36

ProPhase Labs Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ProPhase Labs's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=53.081+(0.639+-3.7747582837255E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.643+0+2)
=56.36

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=59.871-3.508
=56.36

ProPhase Labs's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=53.081+(0.639+-3.7747582837255E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.643+0+2)
=56.36

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=59.871-3.508
=56.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $56.36 Mil mean?
ProPhase Labs (PRPH) has a Total Liabilities of $56.36 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ProPhase Labs and its competitors.
Is ProPhase Labs' Total Liabilities too high?
ProPhase Labs' current Total Liabilities is $56.36 Mil.
How does ProPhase Labs' Total Liabilities compare to NSTM and IDTA?
ProPhase Labs' Total Liabilities of $56.36 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ProPhase Labs and its competitors. ProPhase Labs's current Total Liabilities is $56.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.10 — trading 84.6% below its estimated fair value. The current Total Liabilities is $56.36 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Total Liabilities is $56.36 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.